A Next-Generation Platform for Predicting Human Immune Responses to IgG Antibodies

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Science Immunology  https://doi.org/10.1126/sciimmunol.ady7328 
Dr. Karel F. A. Van Damme  et al.

Points

This research consortium developed a next generation mouse model that features humanized receptors to more accurately predict the biological effects and potential side effects of antibody based medicines in human patients.
Standard preclinical models often fail to identify dangerous immune responses because significant differences exist between how human and animal receptors interact with the tail regions of therapeutic immunoglobulin G antibodies.
The newly engineered platform incorporates human neonatal receptors to improve pharmacokinetic modeling and includes humanized receptors on platelets to detect life threatening blood clotting risks overlooked by conventional testing methods.
By replicating human immune biology and inflammatory responses this technology allows drug developers to conduct head to head comparisons of various antibody designs to select the most effective candidates much earlier.
Enhancing the predictability of early stage testing can significantly reduce the high costs associated with late stage clinical trial failures while simultaneously improving safety for patients during the drug development process.

Summary

This research identifies a next-generation platform designed to address the high clinical failure rates of antibody-based therapeutics. Conventional preclinical models, including murine and macaque systems, often yield misleading data due to substantial interspecies differences in the expression and function of Fc gamma (Fcγ) receptors. In humans, the Fc domain of Immunoglobulin G (IgG) triggers critical immune effector functions or side effects—such as the platelet activation and subsequent thrombosis observed in anti-CD40L trials—that are frequently invisible in standard laboratory models.

To improve translational accuracy, the consortium developed a mouse model utilizing a precise genetic “knock-in” strategy to replace murine receptors with a humanized Fcγ receptor repertoire, including FcγRI (CD64), FcγRIIA (CD32A), FcγRIIB (CD32B), FcγRIIIA (CD16A), and FcγRIIIB (CD16B). These receptors are expressed under the control of human promoters to ensure physiological distribution across immune cell types. Additionally, the model incorporates the human neonatal Fc receptor (FcRn) to more faithfully replicate human antibody pharmacokinetics and half-life, providing a biologically relevant environment for evaluating antibody-receptor interactions.

Validation across multiple disease states demonstrated that the platform can reliably rank antibody candidates by biological effectiveness and cellular depletion capacity. The model accurately reflects how cytokines modulate receptor expression during inflammation, allowing for head-to-head comparisons of subtle molecular designs. By detecting human-specific toxicities and efficacy profiles earlier in the development cycle, this platform serves as a critical tool for reducing late-stage clinical failures, lowering research costs, and enhancing patient safety in the transition from laboratory to clinical application.

Link to the article: https://www.science.org/doi/10.1126/sciimmunol.ady7328

References

Van Damme, K. F. A., Sichien, D., Van Der Borght, K., Van Moorleghem, J., Van Gassen, S., Jorssen, J., De Winter, S., De Leeuw, E., Wang, C., Chai, Q., Zumsteg, A. B., Schmid, M. A., Bosteels, V., De Bleser, P., Vanheerswynghels, M., De Prijck, S., Bujko, A., De Nolf, C., Schuijs, M. J., … Lambrecht, B. N. (2026). Cross-species cellular mapping and humanization of Fcγ receptors to advance antibody modeling. Science Immunology, 11(115), eady7328. https://doi.org/10.1126/sciimmunol.ady7328